Cours suspendu

Communiqués DermTech

Actions

DMTK

US24984K1051

Sociétés holdings

Marché Fermé - OTC Markets Autres places de cotation 19:27:40 12/08/2025			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-.--%	-

12/08/25	DermTech, Inc. cesse ses activités	CI
22/05/25	Quatrième requête de prolongation de la période d'exclusivité approuvée pour DermTech, Inc.	CI

Communiqués

02/09/24	DermTech Completes Transaction for Asset Sale; Operations Continue Under New Ownership and Management	AQ
18/06/24	DermTech Files for Voluntary Chapter 11 Protection	BU
14/05/24	DermTech Reports First-Quarter 2024 Financial Results	BU
10/05/24	DermTech : Accelaration/Increase of Financial Obligation - Form 8-K	PU
18/04/24	DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	BU
01/04/24	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11/03/24	DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	AQ
08/03/24	DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	BU
01/03/24	DermTech : 2023 Q4 Transcript	PU
29/02/24	DermTech Reports Fourth-Quarter 2023 Financial Results	BU
13/02/24	DermTech Announces Release Date for Fourth-quarter 2023 Financial Results	BU
31/01/24	DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations	BU
19/01/24	DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test across All Skin Types	AQ
18/01/24	DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types	BU
17/01/24	DERMTECH SIMPLIFIES THE DERMTECH MELANOMA TEST BY DISCONTINUING THE OPTIONAL TERT ADD-ON ASSAY	AQ
16/01/24	DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay	BU
09/01/24	DERMTECH ANNOUNCES POSITIVE TOPLINE RESULTS FROM TRUST 2 STUDY EVALUATING THE DERMTECH MELANOMA TEST	AQ
08/01/24	DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)	BU
29/12/23	DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	BU
15/12/23	DERMTECH ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	AQ
14/12/23	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
13/12/23	DERMTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against DermTech, Inc. and Encourages Investors to Contact the Firm	BU
21/11/23	DMTK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Case	BU
02/11/23	DermTech Reports Third-Quarter 2023 Financial Results	BU
18/10/23	DMTK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	BU